Kyverna Therapeutics (KYTX) Competitors

$9.49 -1.25 (-11.64%)

Closing price 04:00 PM Eastern

Extended Trading

$9.62 +0.14 (+1.42%)

As of 07:55 PM Eastern

KYTX vs. RLAY, KOD, IDYA, MLYS, and NBTX

Should you buy Kyverna Therapeutics stock or one of its competitors? MarketBeat compares Kyverna Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kyverna Therapeutics include Relay Therapeutics (RLAY), Kodiak Sciences (KOD), IDEAYA Biosciences (IDYA), Mineralys Therapeutics (MLYS), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical products" industry.

How does Kyverna Therapeutics compare to Relay Therapeutics?

Kyverna Therapeutics (NASDAQ:KYTX) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kyverna Therapeutics has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market.

Kyverna Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 216.12%. Relay Therapeutics has a consensus target price of $20.56, suggesting a potential upside of 68.49%. Given Kyverna Therapeutics' higher possible upside, equities analysts plainly believe Kyverna Therapeutics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, Kyverna Therapeutics had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 8 mentions for Kyverna Therapeutics and 6 mentions for Relay Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.55 beat Relay Therapeutics' score of 0.34 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Relay Therapeutics' return on equity of -43.94% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Relay Therapeutics	N/A	-43.94%	-40.11%

Kyverna Therapeutics has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Relay Therapeutics	$15.35M	152.27	-$276.48M	-$1.57	N/A

Summary

Relay Therapeutics beats Kyverna Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Kodiak Sciences?

Kyverna Therapeutics (NASDAQ:KYTX) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

Kyverna Therapeutics has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.32, meaning that its share price is 132% more volatile than the broader market.

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by insiders. Comparatively, 45.9% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Kodiak Sciences had 12 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 20 mentions for Kodiak Sciences and 8 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.55 beat Kodiak Sciences' score of 0.52 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kodiak Sciences	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyverna Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 216.12%. Kodiak Sciences has a consensus target price of $42.14, suggesting a potential upside of 13.84%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Kyverna Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Kyverna Therapeutics' return on equity of -81.88% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Kodiak Sciences	N/A	-253.85%	-81.48%

Kodiak Sciences is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

Summary

Kyverna Therapeutics beats Kodiak Sciences on 8 of the 13 factors compared between the two stocks.

How does Kyverna Therapeutics compare to IDEAYA Biosciences?

Kyverna Therapeutics (NASDAQ:KYTX) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

Kyverna Therapeutics has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market.

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Kyverna Therapeutics had 4 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 8 mentions for Kyverna Therapeutics and 4 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.86 beat Kyverna Therapeutics' score of 0.55 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyverna Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 216.12%. IDEAYA Biosciences has a consensus target price of $50.69, suggesting a potential upside of 79.68%. Given Kyverna Therapeutics' higher possible upside, research analysts plainly believe Kyverna Therapeutics is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82

IDEAYA Biosciences' return on equity of -14.24% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

IDEAYA Biosciences has higher revenue and earnings than Kyverna Therapeutics. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
IDEAYA Biosciences	$218.71M	11.33	-$113.70M	-$1.60	N/A

Summary

IDEAYA Biosciences beats Kyverna Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and Kyverna Therapeutics (NASDAQ:KYTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A

Mineralys Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market.

In the previous week, Mineralys Therapeutics had 15 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 23 mentions for Mineralys Therapeutics and 8 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.55 beat Mineralys Therapeutics' score of -0.01 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyverna Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.5% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 18.9% of Mineralys Therapeutics shares are owned by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Mineralys Therapeutics' return on equity of -27.92% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
Kyverna Therapeutics	N/A	-81.88%	-64.87%

Mineralys Therapeutics presently has a consensus target price of $49.33, suggesting a potential upside of 80.18%. Kyverna Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 216.12%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Mineralys Therapeutics beats Kyverna Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Kyverna Therapeutics (NASDAQ:KYTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Nanobiotix has higher revenue and earnings than Kyverna Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	67.77	-$27.11M	N/A	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A

Nanobiotix has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market.

In the previous week, Kyverna Therapeutics had 5 more articles in the media than Nanobiotix. MarketBeat recorded 8 mentions for Kyverna Therapeutics and 3 mentions for Nanobiotix. Kyverna Therapeutics' average media sentiment score of 0.55 beat Nanobiotix's score of 0.30 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyverna Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Nanobiotix's return on equity of 0.00% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Kyverna Therapeutics	N/A	-81.88%	-64.87%

Nanobiotix presently has a consensus target price of $26.67, suggesting a potential downside of 48.22%. Kyverna Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 216.12%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Kyverna Therapeutics beats Nanobiotix on 7 of the 12 factors compared between the two stocks.

Get Kyverna Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYTX vs. The Competition

Export

Metric	Kyverna Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$576.90M	$3.32B	$6.23B	$12.27B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-2.89	18.21	20.16	25.23
Price / Sales	N/A	283.20	542.01	73.12
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	2.95	6.72	9.81	6.90
Net Income	-$161.31M	$24.16M	$3.56B	$333.88M
7 Day Performance	1.50%	3.88%	0.27%	0.01%
1 Month Performance	0.96%	-3.02%	-0.98%	1.75%
1 Year Performance	335.32%	68.84%	36.22%	32.67%

Kyverna Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYTX Kyverna Therapeutics	2.9229 of 5 stars	$9.49 -11.6%	$30.00 +216.1%	+399.5%	$576.90M	N/A	N/A	96	Earnings Report Analyst Forecast
RLAY Relay Therapeutics	2.6569 of 5 stars	$12.94 +0.7%	$20.56 +58.8%	+361.4%	$2.48B	$15.35M	N/A	330	Insider Trade Gap Down
KOD Kodiak Sciences	1.717 of 5 stars	$39.54 -0.8%	$42.14 +6.6%	+882.2%	$2.47B	N/A	N/A	90	Analyst Revision Gap Down
IDYA IDEAYA Biosciences	3.494 of 5 stars	$28.10 -0.1%	$50.69 +80.4%	+68.7%	$2.47B	$218.71M	N/A	80
MLYS Mineralys Therapeutics	3.6042 of 5 stars	$29.27 -1.5%	$49.14 +67.9%	+80.5%	$2.41B	N/A	N/A	28	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYTX) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kyverna Therapeutics (KYTX) Competitors

KYTX vs. RLAY, KOD, IDYA, MLYS, and NBTX

How does Kyverna Therapeutics compare to Relay Therapeutics?

Summary

How does Kyverna Therapeutics compare to Kodiak Sciences?

Summary

How does Kyverna Therapeutics compare to IDEAYA Biosciences?

Summary

How does Kyverna Therapeutics compare to Mineralys Therapeutics?

Summary

How does Kyverna Therapeutics compare to Nanobiotix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX vs. The Competition

Kyverna Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kyverna Therapeutics (KYTX) Competitors

KYTX vs. RLAY, KOD, IDYA, MLYS, and NBTX

How does Kyverna Therapeutics compare to Relay Therapeutics?

Do insiders and institutionals have more ownership in KYTX or RLAY?

Which has more risk and volatility, KYTX or RLAY?

Do analysts recommend KYTX or RLAY?

Does the media refer more to KYTX or RLAY?

Is KYTX or RLAY more profitable?

Which has preferable valuation & earnings, KYTX or RLAY?

Summary

How does Kyverna Therapeutics compare to Kodiak Sciences?

Which has more volatility & risk, KYTX or KOD?

Do institutionals and insiders have more ownership in KYTX or KOD?

Does the media refer more to KYTX or KOD?

Do analysts recommend KYTX or KOD?

Is KYTX or KOD more profitable?

Which has better valuation and earnings, KYTX or KOD?

Summary

How does Kyverna Therapeutics compare to IDEAYA Biosciences?

Which has more volatility & risk, KYTX or IDYA?

Do institutionals and insiders have more ownership in KYTX or IDYA?

Does the media refer more to KYTX or IDYA?

Do analysts recommend KYTX or IDYA?

Is KYTX or IDYA more profitable?

Which has better valuation and earnings, KYTX or IDYA?

Summary

How does Kyverna Therapeutics compare to Mineralys Therapeutics?

Which has stronger earnings & valuation, MLYS or KYTX?

Which has more volatility & risk, MLYS or KYTX?

Does the media prefer MLYS or KYTX?

Do insiders & institutionals hold more shares of MLYS or KYTX?

Is MLYS or KYTX more profitable?

Do analysts rate MLYS or KYTX?

Summary

How does Kyverna Therapeutics compare to Nanobiotix?

Which has stronger earnings & valuation, NBTX or KYTX?

Which has more volatility & risk, NBTX or KYTX?

Does the media prefer NBTX or KYTX?

Do insiders & institutionals hold more shares of NBTX or KYTX?

Is NBTX or KYTX more profitable?

Do analysts rate NBTX or KYTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX vs. The Competition

Kyverna Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools